Rahul S. Dalal, MD, MPH (@rahulsdalalmd) 's Twitter Profile
Rahul S. Dalal, MD, MPH

@rahulsdalalmd

Gastroenterologist & #IBD specialist @BrighamGI @HarvardMed | #UC pt |📚 MPH @HarvardChanSPH, GI/IBD @BrighamGI, IM @PennMedicine, MD @BrownMedicine, BS @Yale

ID: 1213890301468692480

calendar_today05-01-2020 18:29:41

166 Tweet

571 Followers

248 Following

Rahul S. Dalal, MD, MPH (@rahulsdalalmd) 's Twitter Profile Photo

🥰Honored to join the inaugural #EBMED conference (Apr 20-21) as an early faculty this year! #EBMED is offering opportunities to learn & network with GI experts. Can't make it? Registration offers future free recordings.

🥰Honored to join the inaugural #EBMED conference (Apr 20-21) as an early faculty this year!
#EBMED is offering opportunities to learn & network with GI experts.
Can't make it? Registration offers future free recordings.
Katie Dunleavy (@dunleavy_katie) 's Twitter Profile Photo

How to manage high ostomy output in a patient with #CD & short bowel disease?! #EBMed Excellent presentation by Rahul S. Dalal, MD, MPH Brigham and Women's GI and great discussion by nutrition expert Mount Sinai Division of Gastroenterology Dr Novak on next steps for investigation (including a detailed diet hx) and med rx!

How to manage high ostomy output in a patient with #CD & short bowel disease?! #EBMed 

Excellent presentation by <a href="/RahulSDalalMD/">Rahul S. Dalal, MD, MPH</a> <a href="/BrighamGI/">Brigham and Women's GI</a> and great discussion by nutrition expert <a href="/MountSinaiGI/">Mount Sinai Division of Gastroenterology</a> Dr Novak on next steps for investigation (including a detailed diet hx) and med rx!
Joseph Sleiman, MD, FACP (@josephhabibi_md) 's Twitter Profile Photo

Dr Paul Feuerstadt discusses lapses in implementing the evidence for C diff management. 🤔When will fidoxamicin (1st line) be more affordable? 2025. 💩we are missing out on bezlotoxumab opportunities? 🥲 mistakes in handling restorative microbiota therapy Recording on

Dr Paul Feuerstadt discusses lapses in implementing the evidence for C diff management. 

🤔When will fidoxamicin (1st line) be more affordable? 2025.
💩we are missing out on bezlotoxumab opportunities?
🥲 mistakes in handling restorative microbiota therapy 

Recording on
Camille Lupiáñez-Merly, MD (@camillelupianez) 's Twitter Profile Photo

Come check out our #EBGI Tweetorial 🧵on IBD management during 🤰from the most recent PIANO Registry data! 🦪from Dr. Rahul S. Dalal, MD, MPH: 👉continue ustekinumab or vedolizumab during 🤰 ✋worse perinatal outcomes are seen with use of corticosteroids or disease flares‼️ ..more👇

Edward Loftus (@edwardloftus2) 's Twitter Profile Photo

Dr Rahul Dalal: comparative effectiveness of tofacitinib vs upadacitinib for ulcerative colitis Rahul S. Dalal, MD, MPH #DDW2024 even after adjusting for severity UPA was 2-3 times more likely to result in steroid free clinical Remisssion David Schwartz

Simon Hong (@simonhongmd) 's Twitter Profile Photo

Important data by Rahul S. Dalal, MD, MPH confirming what many of us are seeing in clinical practice - UPA > TOF for UC; in both unadjusted analyses & after inverse prob tx weighting Digestive Disease Week #DDW2024

Important data by <a href="/RahulSDalalMD/">Rahul S. Dalal, MD, MPH</a> confirming what many of us are seeing in clinical practice - UPA &gt; TOF for UC; in both unadjusted analyses &amp; after inverse prob tx weighting <a href="/DDWMeeting/">Digestive Disease Week</a> #DDW2024
IBDJournal & CC360 (@ibdjournals) 's Twitter Profile Photo

Is Tramadol better for pain management in IBD patients compared to traditional opioids 💊? Perhaps. doi.org/10.1093/ibd/iz… - Strengths: Nationwide cohort with >50k patients 🇩🇰 - Limitations: Unmeasured confounders, doses unknown Rahul S. Dalal, MD, MPH Sonia Friedman Jessica R Allegretti

Rahul S. Dalal, MD, MPH (@rahulsdalalmd) 's Twitter Profile Photo

Just Jessica R Allegretti, MD, MPH, FACG, AGAF giving bookend oral plenaries at #ACG2024 1. Bezlotoxumab+FMT did not reduce #Cdiff recurrence vs #FMT alone 2. Anti-TL1A therapy appears effective and safe for #UC vs placebo Brigham and Women's GI #IBD #RCT #Biologics

Just <a href="/DrAllegrettiIBD/">Jessica R Allegretti, MD, MPH, FACG, AGAF</a> giving bookend oral plenaries at #ACG2024

1. Bezlotoxumab+FMT did not reduce #Cdiff recurrence vs #FMT alone

2. Anti-TL1A therapy appears effective and safe for #UC vs placebo 

<a href="/BrighamGI/">Brigham and Women's GI</a> #IBD #RCT #Biologics
ACG (@amcollegegastro) 's Twitter Profile Photo

Introducing the Early Career Leadership Program #ECLP 2025 cohort! These GI physicians will complete training in leadership and policy skills and convene with other #ACGInstitute programs at #LeadershipYOU in June 2025. 🎉Congratulations! #ACGfamily #FutureofGI Neena S Abraham MD MACG FASGE AGAF

Introducing the Early Career Leadership Program #ECLP 2025 cohort!

These GI physicians will complete training in leadership and policy skills and convene with other #ACGInstitute programs at #LeadershipYOU in June 2025.

🎉Congratulations!
#ACGfamily #FutureofGI <a href="/NeenaSAbrahamMD/">Neena S Abraham MD MACG FASGE AGAF</a>
Rahul S. Dalal, MD, MPH (@rahulsdalalmd) 's Twitter Profile Photo

Predictors for chronic opioid use in patients with inflammatory bowel disease – a population based cohort study in AJG - The American Journal of Gastroenterology journals.lww.com/ajg/abstract/9… In >40,000 #IBD pts, ~25% became chronic #opioid users! Predictors were: 💊prior surgery 💊hypnotic/sedative use 💊age > 50 y